title: Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfected and HIV monoinfected patients.
abstract: The hepatic safety profile of ART including DRV/r was retrospectively evaluated in antiretroviral-experienced HIV-infected patients (18 HIV/HCV coinfected, group A and 29 infected with HIV alone, group B) during a 72 week study. During the study, liver enzyme values were higher in group A, but in the case of abnormal transaminase levels, the median values did not exceed 1.6xULN. This study showed evidence of long-lasting hepatic safety of ART including PI DRV/r in HIV/HCV coinfected and in HIV monoinfected persons.
authors.affiliation: Department of Infectious Diseases, San Raffaele, Scientific Institute, Milan, Italy. morsica.giulia@hsr.it
authors.forename: Giulia
authors.initials: G
authors.lastname: Morsica
authors.forename: Giampaolo
authors.initials: G
authors.lastname: Bianchi
authors.forename: Sabrina
authors.initials: S
authors.lastname: Bagaglio
authors.forename: Camilla
authors.initials: C
authors.lastname: Conte
authors.forename: Stefania
authors.initials: S
authors.lastname: Salpietro
authors.forename: Lucy
authors.initials: L
authors.lastname: Porrino
authors.forename: Caterina
authors.initials: C
authors.lastname: Uberti-Foppa
mesh_terms: D000328:Adult; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006526:Hepatitis C / Q000503:physiopathology*; D006801:Humans; D008099:Liver / Q000187:drug effects* / Q000201:enzymology*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D019438:Ritonavir / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D017320:HIV Protease Inhibitors; D019438:Ritonavir